公开(公告)号：US20140042875A1

公开(公告)日：2014-02-13

申请号：US13960460

申请日：2013-08-06

申请人： Kazufumi SUENAGA ,  Kenji SHIBATA ,  Kazutoshi WATANABE ,  Akira NOMOTO ,  Fumimasa HORIKIRI

发明人： Kazufumi SUENAGA ,  Kenji SHIBATA ,  Kazutoshi WATANABE ,  Akira NOMOTO ,  Fumimasa HORIKIRI

IPC分类号： H01L41/18 ,  H01L41/22

CPC分类号： H01L41/18 ,  C01G33/006 ,  C01P2002/30 ,  C01P2002/34 ,  C01P2002/72 ,  C01P2004/04 ,  C01P2006/40 ,  C30B23/025 ,  C30B29/22 ,  C30B29/30 ,  H01G5/18 ,  H01L41/0805 ,  H01L41/094 ,  H01L41/1873 ,  H01L41/22 ,  H01L41/253 ,  H01L41/316 ,  Y10T29/42

摘要： A piezoelectric element includes a substrate, and a lower electrode layer, a piezoelectric film represented by a general formula of (NaxKyLiz)NbO3 (0

摘要翻译： 压电元件包括​​基板和下电极层，由通式（NaxKyLiz）NbO 3表示的压电膜（0≤x≤1,0≤y≤1,0≤x≤0.2，x + y + z = 1）和形成在基板上的上电极层。 该压电薄膜具有假立方晶体，四方晶体，正交晶体，单斜晶体或菱方晶体的晶体结构，或具有至少两个晶体结构共存的状态。 通过电子能量损失光谱测量的Na-K吸收边的能量的最大值和最小值之间的差异或者在压电膜的膜厚度方向上的X射线吸收精细结构光谱不是 超过0.8 eV。

公开(公告)号：US20130038176A1

公开(公告)日：2013-02-14

申请号：US13567157

申请日：2012-08-06

申请人： Fumimasa HORIKIRI ,  Kenji SHIBATA ,  Kazufumi SUENAGA ,  Kazutoshi WATANABE ,  Akira NOMOTO

发明人： Fumimasa HORIKIRI ,  Kenji SHIBATA ,  Kazufumi SUENAGA ,  Kazutoshi WATANABE ,  Akira NOMOTO

IPC分类号： H01L41/04 ,  H01L41/22 ,  H01L41/047

CPC分类号： H01L41/332 ,  H01G5/18 ,  H01L41/047 ,  H01L41/0477 ,  H01L41/0805 ,  H01L41/094 ,  H01L41/1873

摘要： A manufacturing method of a piezoelectric film element includes forming a piezoelectric film including a lead-free alkali niobate based compound having a perovskite structure represented by a compositional formula of (K1-xNax)NbO3 on a substrate, and dry-etching the piezoelectric film by using a low-pressure plasma including a fluorine system reactive gas.

摘要翻译： 压电薄膜元件的制造方法包括：在基板上形成具有由（K1-xNax）NbO3组成式表示的钙钛矿结构的无铅碱铌酸酯系化合物的压电膜，并通过以下方式对压电膜进行干法蚀刻 使用包含氟系反应气体的低压等离子体。

公开(公告)号：US20110251385A1

公开(公告)日：2011-10-13

申请号：US13169782

申请日：2011-06-27

申请人： Masahiro OKUYAMA ,  Fumiaki UEHARA ,  Hiroshi IWAMURA ,  Kazutoshi WATANABE

发明人： Masahiro OKUYAMA ,  Fumiaki UEHARA ,  Hiroshi IWAMURA ,  Kazutoshi WATANABE

IPC分类号： C07D413/14

CPC分类号： C07D265/30 ,  C07D265/32

摘要： The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification.The present invention also relates to a production method of an compound represented by the formula 55, which includes the following steps: wherein each symbol is as defined in the specification.According to the production method of the present invention, an optically active 2-aryl-substituted morpholine compound and 3-oxo-3-(pyrimidin-4-yl)propionate, which are important as starting materials for synthesizing 2-(2-arylmorpholin-4-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one having a tau protein kinase 1 inhibitory activity and useful as a therapeutic drug for Alzheimer's disease and the like, can be produced in a high yield by an industrially advantageous method.

摘要翻译： 本发明涉及由式10表示的光学活性吗啉化合物的制备方法，其包括以下步骤：其中各符号如说明书中所定义。 本发明还涉及由式55表示的化合物的制备方法，其包括以下步骤：其中每个符号如说明书中所定义。 根据本发明的制备方法，光学活性2-芳基取代的吗啉化合物和3-氧代-3-（嘧啶-4-基）丙酸酯作为合成2-（2-芳基吗啉） -4-基）-1-甲基-1H- [4,4']二嘧啶基-6-酮，其具有tau蛋白激酶1抑制活性，可用作阿尔茨海默氏病等的治疗药物，可以以高 通过工业上有利的方法得到。

公开(公告)号：US20110257392A1

公开(公告)日：2011-10-20

申请号：US13169799

申请日：2011-06-27

申请人： Masahiro OKUYAMA ,  Fumiaki UEHARA ,  Hiroshi IWAMURA ,  Kazutoshi WATANABE

发明人： Masahiro OKUYAMA ,  Fumiaki UEHARA ,  Hiroshi IWAMURA ,  Kazutoshi WATANABE

IPC分类号： C07D413/14

CPC分类号： C07D265/30 ,  C07D265/32

摘要： The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification.The present invention also relates to a production method of an compound represented by the formula 55, which includes the following steps: wherein each symbol is as defined in the specification.According to the production method of the present invention, an optically active 2-aryl-substituted morpholine compound and 3-oxo-3-(pyrimidin-4-yl)propionate, which are important as starting materials for synthesizing 2-(2-arylmorpholin-4-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one having a tau protein kinase 1 inhibitory activity and useful as a therapeutic drug for Alzheimer's disease and the like, can be produced in a high yield by an industrially advantageous method.

公开(公告)号：US20120252812A1

公开(公告)日：2012-10-04

申请号：US13467302

申请日：2012-05-09

申请人： Kenji FUKUNAGA ,  Kazutoshi WATANABE ,  Pascal BARNEOUD ,  Jesus BENAVIDES ,  Jeremy PRATT

发明人： Kenji FUKUNAGA ,  Kazutoshi WATANABE ,  Pascal BARNEOUD ,  Jesus BENAVIDES ,  Jeremy PRATT

IPC分类号： A61K31/5377 ,  A61P25/00 ,  A61P3/10 ,  A61P25/28

CPC分类号： C07D413/14

摘要： A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

摘要翻译： 由式（I）表示的化合物或其药学上可接受的盐：用于预防和/或治疗由tau蛋白激酶1的异常活性（例如神经变性疾病（例如阿尔茨海默病））引起的疾病。

公开(公告)号：US20100097246A1

公开(公告)日：2010-04-22

申请号：US12579903

申请日：2009-10-15

申请人： Kazutoshi WATANABE ,  Hideaki Nagakubo ,  Takenobu Kimura ,  Koichi Yamamoto ,  Katsuyki Katayama ,  Naomi Sato ,  Naoya Akiyama ,  Shinichiro Kimura ,  Masahiro Ishida ,  Naoki Yamada ,  Keiji Takagi ,  Toshinobu Hosaka

发明人： Kazutoshi WATANABE ,  Hideaki Nagakubo ,  Takenobu Kimura ,  Koichi Yamamoto ,  Katsuyki Katayama ,  Naomi Sato ,  Naoya Akiyama ,  Shinichiro Kimura ,  Masahiro Ishida ,  Naoki Yamada ,  Keiji Takagi ,  Toshinobu Hosaka

IPC分类号： H03M11/00

CPC分类号： G06F3/0202 ,  H01H13/83 ,  H01H2219/044 ,  H01H2219/056 ,  H01H2219/06 ,  H01H2219/062

摘要： An input device includes a plurality of manipulation portions; an input function portion manipulated by the manipulation portions to perform an input function; a light guiding sheet facing the rear side of the plurality of manipulation portions; and a light source applying light into the light guiding sheet, wherein a rear surface opposite to a front surface of the light guiding sheet facing the manipulation portions is provided with a plurality of concave portions which is depressed to the inside of the light guiding sheet, wherein each concave portion has a circular opening and an inner surface which is a smooth concave curve surface, and wherein light propagated through the inside of the light guiding sheet is reflected by the inner surface toward the inside of the light guiding sheet, and the light is applied from the front surface of the light guiding sheet to the manipulation portions.

摘要翻译： 输入装置包括多个操作部分; 由操作部分操纵以输入功能的输入功能部分; 面向所述多个操作部的后侧的导光片; 以及向所述导光片施加光的光源，其中与所述导光片的面对所述操作部的前表面相对的后表面设置有多个凹陷部，所述凹部被压向所述导光片的内部， 其特征在于，每个凹部具有圆形开口和内表面，该内表面是光滑的凹曲面，并且其中通过导光片的内部传播的光被内表面朝向导光片的内部反射，并且光 从导光片的前表面施加到操作部。

公开(公告)号：US20090124618A1

公开(公告)日：2009-05-14

申请号：US11573476

申请日：2005-09-09

申请人： Kazutoshi WATANABE ,  Fumiaki UEHARA ,  Shinsuke HIKI ,  Toshiyuki KOHARA ,  Kenji FUKUNAGA ,  Satoshi YOKOSHIMA

发明人： Kazutoshi WATANABE ,  Fumiaki UEHARA ,  Shinsuke HIKI ,  Toshiyuki KOHARA ,  Kenji FUKUNAGA ,  Satoshi YOKOSHIMA

IPC分类号： A61K31/5377 ,  C07D413/14

CPC分类号： C07D413/14

摘要： A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C1-C12 alkyl; R2 represents a hydrogen atom, or the like; R′ represents a C1-C6 alkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C1-C6 alkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

摘要翻译： 由式（I）表示的化合物，其光学活性异构体或其药学上可接受的盐：其中X表示CH或N; 表示C1-C12烷基; R2表示氢原子等; R'表示C1-C6烷基等; q表示0或1〜7的整数， Y表示C1-C6烷基等; p表示0或1〜5的整数， R表示2,3-二氢吲哚基等，其用于预防和/或治疗由tau蛋白激酶1多动症如神经变性疾病（例如阿尔茨海默病）引起的疾病。